Pfizer Animal Health & Jilin Guoyuan Announce Animal Vaccine Joint Venture In China

Pfizer And Guoyuan have formed a joint venture to expand development, manufacture, and distribution of animal vaccines in China, with an initial focus on swine vaccines.

AsianScientist (Sep. 9, 2011) – Pfizer Animal Health, a business unit of Pfizer Inc. and Jilin Guoyuan Animal Health Company, Ltd., announced on Thursday an agreement to jointly develop, manufacture, and distribute animal health vaccines in China.

The new joint venture, Jilin Pfizer Guoyuan Animal Health Co., Ltd., will offer a comprehensive range of vaccine products tailored to help China’s livestock producers meet increasing demand for a safe and abundant supply of pork, beef, dairy, and poultry from healthy animals.

The animal vaccine market in China is valued at US$800 million per year. Pfizer Guoyuan Animal Health will focus initially on developing vaccines to protect the health of swine. Vaccines for swine have high growth potential as China is the world’s leading pork producing nation, with an annual population of more than 600 million pigs.

The joint venture provides a strategic platform for growth in China, a US$3.4 billion animal health market and the second largest worldwide with an expected compound annual growth rate of approximately ten percent.

“The Pfizer Guoyuan joint venture affirms our commitment to invest in and expand our research and development capabilities in China,” said Juan Ramón Alaix, president, Pfizer Animal Health.

“We view China as a global center for innovation. Guoyuan, with its strong vaccine development program and scientific expertise, and newly completed manufacturing capacity in the Huinan Economic Development Zone in Jilin, makes the company the optimal partner for Pfizer Animal Health.”

Dr. Hua Wu, General Manager of Jilin Guoyuan Animal Health Company, Ltd., added:

“Pfizer complements Guoyuan with its world class R&D, manufacturing, regulatory and operational expertise, its founding leadership in the International Veterinary Collaboration for China, a Veterinary Alliance, as well as its growing field force and customer base in China. I believe that Pfizer Guoyuan is well positioned to become the leading innovator of animal health vaccines and the partner of choice for China’s rapidly expanding animal agriculture industries.”

Terms of the agreement were not disclosed. The joint venture is subject to approval by government authorities in China.

——

Source: Pfizer Animal Health.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

Asian Scientist Magazine is an award-winning science and technology magazine that highlights R&D news stories from Asia to a global audience. The magazine is published by Singapore-headquartered Wildtype Media Group.

Related Stories from Asian Scientist